About Ovoca Bio Plc

Company Description

Ovoca Bio is a clinical-stage biopharmaceutical company focused on women’s health. In 2018 the Company acquired control of IVIX, a biotechnology company developing Orenetide (BP-101), a novel medicinal treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). Since the initial acquisition, Ovoca Bio has supported the continued clinical development and commercial planning of Orenetide, which has been submitted for marketing authorisation in Russia and has commenced a Phase II study in a western population with HSDD. In March 2020, Orenetide became a fully owned program of Ovoca Bio.

Founded and incorporated in Ireland, the business currently operates in Ireland, the UK and Russia.

Year founded


Served area

Irland, UK, Russia

Shareholder information

Shares outstanding



Dec. 14, 2018

Stock exchange(s)

Euronext Dublin



Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.